|Bid||5.78 x 7300|
|Ask||5.85 x 500|
|Day's Range||5.50 - 5.99|
|52 Week Range||4.41 - 9.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.92|
Aurinia Pharmaceuticals Inc’s (NASDAQ:AUPH): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The US$447.14MRead More...
The Victoria, British Columbia-based company said it had a loss of 4 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in U.S.
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
NEW YORK, March 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Aurinia Pharmaceuticals Inc., today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, after the market closes.
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Michael Hayden, CM OBC MB ChB PhD FRCP FRSC to its board of directors.
Aurinia Pharmaceuticals Inc., today announced it has received this year’s Company of the Year Award from LifeSciences BC. The 2018 LifeSciences BC award winners will be recognized at this year’s annual dinner presented by FARRIS, held on April 19, 2018 in Vancouver.
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis .
High growth companies such as Firan Technology Group and Aurinia Pharmaceuticals has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companiesRead More...
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Joseph P.
Aurinia Pharmaceuticals Inc., today announced that its Chief Executive Officer, Richard M. Glickman and Celia Economides, Vice President, Corporate and Public Affairs, will participate in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference on February 14th at 2:30pm ET.
The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon — not from the renewed interest in biotech stocks but because of Aurina’s upcoming revenue potential. Aurina has a potential blockbuster drug, called Voclosporin, that is in the clinical stages. AUPH’s priorities during both its second and third quarter were the Aurora Phase III trial.
NEW YORK, NY / ACCESSWIRE / January 5, 2018 / On Thursday, all three major indexes rose for the third consecutive day, with the Dow Jones crossing the 25,000 plateau for the first time ever. The Dow Jones ...
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) fell nearly 5% in after-hours trading Thursday after it notified the SEC and shareholders that it would be able to sell up to $250 million in newly issued common stock as needed over a specified amount of time. This new "shelf registration," as it's called, replaced the previous registration that spanned the prior 25 months. If all shares under the new shelf registration are sold, it would result in significant dilution -- 60%.
Aurinia Pharmaceuticals Inc. today announced that in order to replace its prior expired base shelf prospectus and corresponding shelf registration statement it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces of Ontario, Alberta and British Columbia in Canada, and a corresponding shelf registration statement on Form F-10 with the U.S....
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market open on Monday, December 18 2017.
Aurinia Pharmaceuticals Inc., announced today that it has been selected for addition to the NASDAQ Biotechnology Index® , which will become effective prior to market open on Monday, December 18, 2017.
High growth companies such as Canopy Growth and Aurinia Pharmaceuticals has a positive future outlook in terms of their returns, profitability and cash flows. The prospects of these companies tendRead More...
Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal study in lupus nephritis (LN), Canaccord analyst Neil Maruoka continues to be largely bullish on this biotech player. The company's LN asset voclosporin between strong efficacy and a standout safety profile could attract some global attention for a partnering opportunity that has secured an eager bull in Maruoka.